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Abstract
Background: Pregnancy is associated with improvement in immunoregulation that persists into 
the geriatric phase. Impaired immunoregulation is implicated in Alzheimer’s disease (AD) 
pathogenesis. Hence, we investigate the relationship between pregnancy and AD.
Methods: Cross-sectional cohort of British women (N = 95). Cox proportional hazards modeling 
assessed the putative effects of cumulative months pregnant on AD risk and the mutually adjusted 
effects of counts of first and third trimesters on AD risk.
Results: Cumulative number of months pregnant, was associated with lower AD risk (β = −1.90, 
exp(β) = 0.15, P = .02). Cumulative number of first trimesters was associated with lower AD risk 
after adjusting for third tri-mesters (β = −3.83, exp(β) = 0.02, P < .01), while the latter predictor 
had no significant effect after adjusting for the former.
Conclusions: Our observation that first trimesters (but not third trimesters) conferred protection 
against AD is more consistent with immunologic effects, which are driven by early gestation, than 
estrogenic exposures, which are greatest in late gestation. Results may justify future studies with 
immune biomarkers.
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Introduction
Inflammatory processes are implicated in the pathogenesis of Alzheimer’s disease (AD).1,2 
Reproductive life history is known to influence inflammatory pathways and affect 
inflammatory disease activity, both in terms of short-term symptomology (eg, asthma,3 
rheumatoid arthritis,4,5 multiple sclerosis6) and long-term risk (eg, allergies,7,8 systemic 
sclerosis,9,10 rheumatoid arthritis4,11,12). Pregnancy is an especially important modifier of 
women’s inflammatory activity. Inflammation as a possible link warrants an investigation of 
whether a woman’s pregnancy history influences her AD risk. Only a small number of 
studies have addressed the possibility that aspects of reproductive life history might 
influence AD risk, and authors largely ignore inflammation in discussing those results. We 
critically evaluate these studies and further discuss how reproductive life history affects risk 
of other maladies with similar etiologies. Using data collected from our cross-sectional study 
of British women, we explore the possibility that women’s pregnancy life history influences 
risk of Alzheimer’s-type dementia.
Alzheimer’s and Adaptive Immunity
There is abundant evidence to support the concept that AD is a systemic inflammatory 
disease.13,14 A full review of inflammation in AD is beyond the scope of this article, but 
given the ways in which pregnancy modifies the adaptive immune system, it is important to 
highlight the role of T-cells in AD etiology. T-cells are more numerous in the AD brain than 
healthy brains,15,16 potentially as a result of the blood– brain barrier dysregulation that is 
typical of AD neuropathy.17 Participants with AD exhibit more activated T-cells both in the 
periphery and the brain compared to age-matched controls.18 This increase in T-cells has 
been attributed to the CD4+ compartment,14,19 with greater concentrations of effector 
memory cells (CD45RA−CCR7−), specifically late differentiated cells (CD28−CD27−), and 
lower concentrations of early differentiated (CD28+CD27+) and naive CD4+ cells (CD45RA
−CCR7+).20,21
Characterization of the upregulated CD4+ cells in AD reveals that among individuals with 
AD, excessive inflammation is exhibited that is type 1 dominant, with elevated levels of 
TH1-associated cytokines.2,22–24 TH1 cells can influence AD pathogenesis both from within 
the brain and from the periphery: Pro-inflammatory cytokines secreted by activated TH1 
cells in the periphery can cross the blood–brain barrier and activate dendritic cells, 
microglia, and astrocytes, and amyloid-b has an activating effect on microglia and 
astrocytes, stimulating preferential TH1 proliferation.16 Importantly, while individuals with 
AD exhibit proliferation of effector CD4+ cells, this is not the case for the CD4+ cells with a 
suppressive phenotype, regulatory T-cells (TRegs; CD25+FoxP3+CD127low).21 In healthy 
individuals, sufficient TReg supply regulates effector T-cell activity and prevents excessive 
inflammation. It has been suggested that insufficient TReg repositories may contribute to AD 
pathogenesis.20,21
Converging evidence suggests that alterations in CD4+ subset concentrations may be an 
early hallmark of AD, potentially contributing to the pathological cascade.25,26 Upregulation 
of late differentiated T-cells and depletion of naive T-cells and TRegs are apparent during the 
preclinical (mild cognitive impairment [MCI]) and early stages of AD symptomology19 and 
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do not appear to change over the course of AD progression.21 Rodent models of AD support 
the notion that the immunological changes characteristic of AD occur before neurocognitive 
deterioration,26 and experimental amplification of TReg response delays onset27 and can 
even reverse AD-like cognitive impairment.28 These AD-characteristic immune profiles 
described here do not occur in individuals with other dementias,19,29 supporting the 
likelihood that this inflammatory profile is specific to AD. Individuals with AD do not 
exhibit greater degrees of immunosenescence than age-matched controls,30 suggesting that 
neurotypical “inflammaging” is not responsible for these changes. Inflammaging is a 
concept developed by Franceschi et al31 to describe typical, age-related, chronic, low-grade 
inflammation characterized by immunosenescence, but patients with AD do not exhibit 
higher concentrations of pro-inflammatory biomarkers C-reactive protein and interleukin 6 
compared to controls.30
Pregnancy and Adaptive Immunity
In a woman’s (postnatal) life span, the most dramatic increases in TRegs occur during the 
first trimester of pregnancy. Evidence suggests there are exponential TReg increases in pre- 
and early pregnancy, stable levels across late pregnancy, and mild increases postpartum, 
which plausibly could persist for the rest of the life span. Specifically, pregnancy is 
maintained by an increase in TReg cells that, some evidence suggests, could begin as early as 
coitus in response to seminal fluid exposure in preparation for embryo implantation.32–36 
The TReg levels rise further at implantation and during the first 2 pregnancy trimesters.32,37 
Pregnancy-induced TRegs are generated in the periphery38 and migrate to the fetal–maternal 
interface, leading to lower detectable levels of TRegs in the maternal periphery during 
pregnancy.6 In human pregnancy (unlike murine pregnancy38), elevated TReg levels are 
maintained postpartum.39,40 Somerset et al demonstrated that maternal TReg concentrations 
showed a significant increase from prepregnancy to 6 to 8 weeks postpartum (4.4% vs 7.5% 
of peripheral lymphocytes). The TReg levels continue to rise for a year throughout the 
postpartum phase at a rate of 4% increase per month,41 and so maternal peripheral TReg 
frequency is significantly higher postpartum compared with during pregnancy.6 There is 
evidence that within the TReg proliferation that occurs with pregnancy, the TRegs specific for 
fetal antigens are expelled with decidual tissue and those without such specificity are 
retained in the maternal body.39,42,43 It remains unknown how long these changes in T-cell 
subsets persist beyond 1 year postpartum.
While pregnancy induces increases in TRegs that suppress effector T-cells, there is still 
immune activity during pregnancy, and immunosuppression is not complete. The effector 
cells that are upregulated in pregnancy are TH2 dominant, suppressing TH1 inflammation. In 
addition to the maternal immune modifications, the conceptus secretes TH2 cytokines that 
downregulate TH1 cytokines,44 which may influence the maternal compartment.
In sum, the changes that occur in the CD4+ compartment during pregnancy (proliferation of 
TRegs, downregulation of type 1 inflammation) are in direct contrast with the typical profile 
of the CD4+ compartment in AD (depletion of TRegs, upregulation of type 1 inflammation). 
We speculate that if pregnancy’s immunologic alterations persist across the life span, we 
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might expect that women with more pregnancies should benefit from greater protection 
against AD pathogenesis.
Hypotheses
This study tests the overarching hypothesis that women who spend more cumulative time 
pregnant in their lives will experience reduction in AD risk via improvement in 
immunoregulation. To test this hypothesis, our study considers women’s cumulative number 
of months pregnant with relation to AD risk. If pregnancy were to protect against AD via 
greater repositories of TRegs, then cumulative number of months pregnant would be a better 
predictor of AD risk than parity. Cumulative number of first trimesters would be a better 
predictor than parity because the major changes in TReg concentrations during pregnancy 
occur in the early phase, so regardless of whether the pregnancy lasted to completion, the 
benefit from increased concentrations of TRegs might persist.
We acknowledge the possibility that even if we observe that cumulative time pregnant is 
correlated with AD risk, an alternative explanation for this relationship could be related to 
estrogen exposure. Cumulative months pregnant could be a proxy for duration of estrogen 
exposure (via longer reproductive span) or quantity of estrogen exposure (via pregnancy-
associated high concentrations of estrogen). Estrogen levels rise exponentially during 
pregnancy, with typical plasma concentrations during the third trimester of pregnancy 
approximately 85 times levels typical during an ovulatory menstrual cycle (calculated from 
Tulchinsky and Little45). Several in vitro and animal studies have demonstrated estrogen’s 
role in inhibiting and reversing AD-specific brain insults,46–50 and human studies have 
investigated how lifetime duration of endogenous estrogen exposure may influence later-life 
cognitive performance51–55 and AD risk.56–58 It could be hypothesized that this higher dose 
of estrogen exposure might confer reduction in AD risk.
We adopted 2 strategies for distinguishing between an immunologic versus estrogenic 
explanation for pregnancy’s hypothesized effect on AD risk. Firstly, more pregnancies could 
be associated with longer reproductive span, defined as the time between menarche and 
menopause, which has been used as a proxy measure of duration estrogen exposure.59,60 We 
addressed the possibility of cumulative time pregnant acting as a proxy for reproductive span 
by adjusting for reproductive span in all analyses. Secondly, more pregnancies could be 
associated with greater quantity of estrogen exposure. If pregnancy were to protect against 
AD via greater concentrations of estrogen, later pregnancy would exert a more potent anti-
AD effect than early pregnancy because of the exponential nature of estrogen’s increase 
across the course of pregnancy. We addressed the possibility of cumulative months pregnant 
acting as a proxy for high doses of estrogen exposure by conducting 2 separate analyses of 
the reliance of AD risk upon a woman’s cumulative number of first trimesters (proxy for 
immunoregulation) and the reliance of AD risk upon a woman’s cumulative number of third 
trimesters (proxy for estrogenic neuroprotection).
A summary of our hypotheses is that we anticipate (1) cumulative months pregnant will be 
negatively associated with AD risk, (2) cumulative months pregnant will be a better 
predictor of AD risk than parity, and (3) cumulative number of first trimesters will be a 
better predictor of AD risk than cumulative number of third trimesters.
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Methods
Cohort
Women aged 70 to 100 years along with family member(s) and/or carer(s) were recruited for 
participation through nursing homes, churches, community centers, the Alzheimer’s Society, 
and a retired employee community from 2010 to 2012. Participants received a modest gift 
voucher as incentive. The protocol had approval from the University of Cambridge Human 
Biology Research Ethics Committee. Participants were informed of research purpose, 
activities, and confidentiality. Proband, informant (family member or carer), and, when 
necessary, legally authorized representative provided written informed consent.
Procedures
Each session consisted of an interview collecting information about reproductive history and 
factors that would potentially confound the relationship of dementia status with reproductive 
history, including use of contraceptive and menopause hormone therapies. Information was 
collected through detailed interviews with probands, family members, carers, nursing home 
staff, and written records, when necessary and available. Exclusionary criteria included self, 
informant, or carer report of proband having non-Alzheimer’s-type dementia (eg, vascular, 
Parkinsonian) or any possible external injury to the brain (eg, head impact injury, brain 
tumor). Ten cases were excluded from the analysis because of these criteria (Table S1). A 
weakness in the study design was lack of information gathered about immunopathology. 
Dementia status was measured by the Clinical Dementia Rating (CDR) scale, consisting of a 
60- to 90-minute interview conducted in 2 parts, one with the proband and the other with an 
informant, that is, her relative or carer. In the CDR, probands are evaluated in 6 categories: 
memory, orientation, judgment and problem–solving, home and hobbies, community affairs, 
and personal care. The “sum of boxes (SOB)” was used as a continuous variable, as has 
become standard in clinical trials,61,62 computed from the sum of each category score 
creating a scale from 0 to 18. Cases and controls were not distinguished until CDR-SOB 
scores were calculated, at which time individuals scoring “0” were designated as controls. 
Details of the study protocol are described in previous publications.58,63
Variable Calculations
Age at Alzheimer’s onset.—For the purposes of the Cox model, the time-to-event was 
defined as years between age 50 and CDRSOB score turning from 0 to 0.5, indicating onset 
of AD symptoms. This was estimated based on CDR-SOB score at the time of interview. 
Using published AD progression norms64 (typical number of years spent in each dementia 
phase), a scale was created to estimate age at onset for each possible CDR-SOB score by 
interpolating CDR-SOB scores between the end points of other scales’ categories. Year at 
which CDR-SOB score would have progressed from 0 to 0.5 was back-extrapolated from the 
observed degree of dementia at the time of interview. Details of this methodology are 
described in Supplementary Methods.
Predictive variables.—Cumulative months pregnant was calculated in a comprehensive 
manner, such that all pregnancies including miscarriages and medical terminations were 
included. Information was collected about the trimester at which spontaneous and elective 
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abortions occurred. For calculating cumulative months pregnant, number of first trimesters 
and number of third trimesters, we considered a first-trimester pregnancy termination to be 
equivalent to 3 months spent pregnant, and second trimester was considered 6 months (there 
were no third-trimester terminations in this cohort). All child-yielding pregnancies, 
including stillbirths, were included in the variable calculation as 9 months. Parity was 
calculated as each woman’s total number of delivered births, including live births and 
stillbirths. Predictive variables were natural logarithm transformed to improve the symmetry 
of the distributions. Quantification of covariates follows standard procedures and is 
described in Table S2. When necessary, continuous covariates were transformed to improve 
symmetry of distribution. All effect size coefficients were back-transformed for 
interpretability (Figure 1).
Statistical Tests
In a main effects analysis, each predictive variable contributed into the Cox model a 
coefficient, “coef,” whose value is estimated on the basis of the data. When exponentiated, 
“exp(coef),” this parameter yields the ratio of hazards (probability of AD onset per unit 
time) between 2 hypothetical women who are identical except for a unit difference between 
their respective values of the predictive variable. “Alzheimer’s disease-free time” was 
defined as the retrospectively estimated number of years in excess of age 50, prior to the 
interview, during which the woman was free from AD. The AD-free time for those women 
who were judged to be free from AD at the time of the interview was treated as right 
censored, as is common practice in survival analysis. The dependency of AD-free time on 
the predictive variables was analyzed via Cox proportional hazards model. Plots of the 
martingale residuals revealed that the model fits were not unduly influenced by particular 
cases (Figures S1 and S2).
We undertook a 2-step process to select covariates for the Cox models. Firstly, we identified 
all variables that might confound the statistical relationship between pregnancy history and 
AD risk (Table S2). Each of these variables was independently tested for covariance with 
each predictive and outcome variable. Secondly, those variables that exhibited significant (P 
< .10) relationships with both a predictive and an outcome variable were included in models. 
Additionally, 2 interaction terms were included to investigate whether subsets of women 
exhibited different relationships between pregnancy history and AD risk based upon (1) 
whether or not they breastfed and (2) whether or not they had a first-degree relative with 
dementia. These 2 interaction terms were selected because of previously reported 
importance of breastfeeding history and family history of dementia with AD risk in this 
cohort.63
Additionally, for cases (CDR-SOB > 0), we performed a linear regression to check whether 
incomplete pregnancies were statistically related to the degree of dementia (CDRSOB score) 
at interview, in order to determine whether our ability to detect incomplete pregnancies was 
biased related to proband memory impairment.
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Results
Cohort Statistics
To investigate the role of pregnancy history on AD risk in a cohort of British women, a 
subset of 95 women from the total cohort of 133 women were included in the analyses. All 
women were of white British ethnic identity, currently residing in England. Ten probands 
from the initial cohort of 133 were excluded from analyses due to factors that would cause 
non-Alzheimer’s-type dementia (eg, stroke) or could obscure the effects of reproductive 
history (eg, ovarian cancer). Twenty-eight more participants were excluded due to missing 
information (Table S1).
Degree of dementia at the time of interview varied across the full range of possible CDR-
SOB scores, with some of the participants judged to have no sign of cognitive impairment 
(N = 56) and some assessed to have CDR-SOB scores of 0.5 or higher (N = 39) at interview 
(Table 1). Of the controls, 83% were born in England and 86% were educated to age 16 or 
less, and of the cases, 82% were born in England and 92% were educated to age 16 or less. 
Comparing reproductive patterns between the control group and the case group, we observed 
identical median ages at menarche, menopause, similar reproductive spans, and ages at first 
birth. No statistically significant differences existed between cases and controls for any 
reproductive life history variables (Table 1). We investigated potential detection bias in the 
case sample and found no significant relationship between severity of dementia and number 
of incomplete pregnancies in the subset of cases (linear model results: R2 = 0.0, F1,48 = 0.9, 
P = .34). This null result suggests that detection of incomplete pregnancies was not biased 
due to the memory loss associated with degree of dementia. Our methods involving 
interview of informants and consultation of written records may have contributed to greater 
accuracy than participants with dementia could have provided on their own. There were 
significant differences in age at interview, education, and occupation between the case and 
control subsets of the cohort (Table 1). Each of these variables was investigated for covariate 
status (Table S2). Education was found to be correlated with both predictive and outcome 
variables and was therefore included in multivariate models (Table S2).
Hypothesis 1: More Cumulative Months Pregnant Is Associated With Lower Alzheimer’s 
Risk
In a Cox proportional hazards model adjusting for age at first birth, reproductive span, and 
history of breastfeeding, marriages, and occupation, we found that AD risk had a significant 
dependence on cumulative months pregnant, with more months pregnant associated with 
lower AD risk (Table 2). For example, a woman who spent 3% more total months pregnant 
than another (otherwise identical) woman would have approximately 5.50% (25th-75th 
percentiles 3.9–7.0%) lower in AD risk (P = .02), i.e., this would apply to two (otherwise 
identical) women who had spent 34 versus 33 months pregnant. Similarly, 2.8% more total 
months pregnant was associated with 5.5% (25th-75th percentiles 0.5–10.3%) lower AD risk 
(P = .03). These results are consistent with our prediction that pregnancy may exert long-
term protective effects against AD risk potentially due to the benefits of pregnancy-induced 
TReg proliferation but does not rule out other plausible biomechanisms of neuroprotection.
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Hypothesis 2: Cumulative Months Pregnant Is a Better Predictor of AD Risk Than Parity
In a Cox proportional hazards model controlling for age at first birth, reproductive span, and 
history of breastfeeding, marriages, and occupation, we found that the number of births 
(both live childbearing and stillbirths, ie, “parity”) was not significantly associated with the 
risk of AD (P = .21, and P = .11 adjusted for cumulative months pregnant; Table 2). This 
metric, parity, is a less precise reflection of a woman’s full pregnancy history than 
cumulative months pregnant and has been the construct of interest in previous studies.
Hypothesis 3: Cumulative Number of First Trimesters Is a Better Predictor of AD Risk Than 
Third Trimesters
In separate Cox proportional hazards models, all controlling for age at first birth, 
reproductive span, and history of breastfeeding, marriages, and occupation, we assessed AD 
risk reliance on first trimesters alone and third trimesters alone, first while adjusting for third 
trimesters and third while adjusting for first trimesters. We found that AD risk had a 
significant dependence on cumulative number of first trimesters and no significant 
dependence on cumulative number of third trimesters (Table 3). For example, a woman who 
had 20% more first trimesters than another (otherwise identical) woman would have 
approximately 30% (25th-75th percentiles 22.4–36.4%) lower AD risk (P = .02) i.e., this 
would apply to two (otherwise identical) women who had 6 versus 5 total first trimesters. 
Models that measure the reliance of AD risk on first trimesters while adjusting for third 
trimesters, and vice versa, demonstrated similar results (Table 3). Furthermore, the 95% 
confidence interval for the exponentiated coefficients do not overlap (models 6 and 8 in 
Table 3), suggesting that the reduction in AD risk brought by the first 3 months of a new 
pregnancy is greater than that brought by the final 3 months of an ongoing pregnancy (Table 
3). These data provide evidence against the idea that greater quantity of estrogen exposure 
explains pregnancy’s protective effect against AD risk, which would be most dependent on 
third trimesters, and instead support the possibility of an immunoregulatory mechanism, 
which would be most dependent on first trimesters.
Discussion
We find that women who spent more months of life pregnant exhibited a significant, dose-
dependent reduction in AD risk. Our results support the possibility that pregnancy protects 
against later-life AD onset, potentially due to pregnancy’s characteristic increase in TReg 
proliferation. Previous studies found effects in the opposite direction, with higher parity 
associated with earlier onset of AD,55,65 and one study reported that women who had 3 or 
more pregnancies had triple the AD risk.55 It is possible that the inconsistent results for the 
reliance of AD risk between our study versus studies of parity could be due to those studies’ 
neglect of the considerable variation in breastfeeding rates and incomplete pregnancies.
Other studies have explored the relationship between women’s parity and geriatric cognitive 
performance (which may or may not be indicative of AD risk) with mixed results. One study 
found that higher parity was associated with better memory ability in elderly women,53 and 
others have observed that estrogen replacement therapy’s beneficial effect on cognitive 
function improved with increasing parity, although this effect was not statistically 
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significant.66 However, there has been more robust evidence for the opposite trend: One 
study found higher parity associated with worse cognitive function,54 and another found that 
women who had 5 or more pregnancies had worse cognitive impairment compared with 
those who had fewer pregnancies.51 It should be noted that pregnancy’s potential anti-AD 
effect due to improvement in immunoregulation may not be relevant for non-AD-related 
cognitive decline. Therefore, in these studies of non-AD cognitive decline,51,53,54,66 the 
mechanisms and pathways responsible for differences in cognitive performance may be 
considerably different and potentially variable between individuals and study cohorts. 
Further research is necessary to resolve whether failure to consider incomplete pregnancies 
and breastfeeding in studies of AD, as well as whether there may be contradictory risk 
factors for AD and non-AD cognitive decline, accounts for some inconsistencies in previous 
study results.
Immunoregulatory or Estrogenic Pathway?
Our observation that more cumulative months pregnant is associated with reduced AD risk 
could potentially be attributable to a number of explanations. We suggest the most likely 
explanation is related to immunoregulation. Other possible explanations could be that 
cumulative months pregnant is a proxy for duration of estrogen exposure (longer 
reproductive span) or quantity of estrogen exposure (pregnancy-associated high 
concentrations of estrogen). We address these possibilities in 2 ways. Firstly, we attended to 
duration of estrogen exposure by controlling for reproductive span in all models and still 
found that AD had a significant reliance on cumulative months pregnant (Table 2). Secondly, 
we compared cumulative number of first trimesters (mean [M] = 3.0, standard deviation 
[SD] = 1.8) to third trimesters (M = 2.5, SD 1.5). If pregnancy exerts its anti-AD effect via 
recruitment of TRegs, then first trimesters would be expected to exert the stronger effect 
because the most dramatic acceleration in TReg recruitment occurs from the nonpregnant to 
early pregnant state.40,41 Conversely, if pregnancy exerts its anti-AD effect via quantity of 
estrogen exposure, then third trimesters would be expected to exert the stronger effect 
because estrogen levels rise exponentially during pregnancy. Our results are more consistent 
with an immunologic explanation and less with an estrogenic mechanism.
Pregnancy and Autoimmunity
Alzheimer’s disease is characterized by a number of immuno-logic similarities with 
autoimmune diseases, including not only TH1 dominance and insufficient TRegs but also the 
presence of autoantibodies.67,68 There is abundant evidence that pregnancy induces 
protection and relief from autoimmune diseases. Such evidence is consistent with the idea 
that pregnancy induces increases in TRegs that suppress effector T-cells and mildly 
upregulates TH2 inflammation. It has been known since 1938 that pregnancy is associated 
with symptom relief in rheumatoid arthritis,4,5 with many people going into remission 
during pregnancy.9 While previous authors have interpreted this effect with relation to 
estradiol or cortisol, there has been no evidence for such an association,69,70 consistent with 
the possibility that proliferation of TRegs is responsible for the suppression of inflammation 
characteristic of rheumatoid arthritis.71 We posit the protective effect of TRegs in pregnancy 
may have long-term advantages in protection against developing rheumatoid arthritis due to 
increases in TReg cell quantity or activity that are sustained beyond pregnancy. Nulliparous 
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women have twice the risk of rheumatoid arthritis compared to parous women.4,11,12 In 
spondyloarthropathy, another form of inflammatory arthritis, as well as autoimmune 
hepatitis, pregnancy usually has beneficial effects.9,72,73 Additionally, nulliparas have 
increased risk of systemic sclerosis compared with parous women,9,10 representing further 
evidence for a long-term protective effect. Multiple sclerosis is a particularly relevant 
disease to consider in light of AD because it is characterized by neuroinflammation. There is 
significant symptom reduction during pregnancy among women with multiple sclerosis.6 A 
recent study found that individuals with amnesic MCI and multiple sclerosis exhibited 
similar levels of CD45+ T-cells and pro-inflammatory cytokines in cerebrospinal fluid, 
suggesting similar central inflammatory profiles that manifest before AD neurocognitive 
impairment.25
There is also evidence that pregnancy induces protection and relief from atopies, which are 
TH2 dominant. This evidence is consistent with the idea that pregnancy induces increases in 
TRegs that suppress effector T-cells. Pregnancy may induce relief from asthma and 
improvement in bronchial hyperresponsiveness.3 It is noteworthy that the improvement in 
asthma symptoms was observed from preconception through the second trimester, which is 
when TReg cells proliferate, and then there was no statistically significant change between 
the second and third trimester. Interpretation of this trend has not previously included 
discussion of TRegs but rather speculated on the role of sex steroids in asthma 
symptomology.74 There is evidence that increasing parity has a beneficial effect in 
diminishing maternal allergies,7,8 further evidence that pregnancy-induced change in 
adaptive immunity may have long-term effects for the mother.
Further evidence for pregnancy-induced long-term improvements in immunoregulation 
comes from studies of fetal microchimerism. Fetal cells are semi-allogeneic to the mother’s 
genetic identity, and after a pregnancy, fetal cells remain in the mother. It is thought that 
such cells persist in the mother’s body for the duration of her lifetime,75 and thus a woman 
with multiple pregnancies would carry fetal microchimeric cells of multiple genetic 
identities. It has been postulated that maternal lymph nodes might contain increased levels of 
TRegs in order to sustain an immunosuppressed environment to facilitate tolerance of these 
populations of semiallogeneic cells,75 as has been demonstrated in fetal lymph nodes to 
sustain tolerance of alloantigens.76
Research Considerations
Limitations of this study include the small sample size, potential for recall inaccuracies or 
biases which may be higher than in other cohorts due to this cohort’s age range and 
dementia status, lack of biomarker data, lack of full medical history, and lack of information 
on causes of miscarriage, although it would be nearly impossible to find causal information 
from miscarriages that occurred as early as the 1920s. Furthermore, our data cannot test (or 
rule out) the possibility that estrogenic neuroprotection requires merely a mild elevation in 
estrogen concentration, and so the extremely high concentrations of third-trimester estrogen 
may be irrelevantly above the necessary threshold for reduction of AD risk. We also cannot 
rule out the possibility that another unknown biological pathway connects pregnancy and 
AD etiology.
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The relationship between miscarriage and inflammation is unlikely to confound our model. 
Firstly, we address the issue of inflammation as a cause of incomplete pregnancies in this 
cohort. Sporadic miscarriage (occurring after a missed period and therefore known to the 
proband) is a common and normal part of a woman’s reproductive experience, affecting an 
estimated 1 in 4 pregnancy-attemptant women77 and 15% of pregnancies.78,79 There are 
myriad causes of sporadic miscarriage, most often and nonexclusively chromosomal 
abnormalities (observed in 75% of cases) and fetal malformation (observed in 85% of 
cases),80 in addition to uterine abnormalities, cervical compromise, endocrine dysregulation, 
and toxic exposure.79 In some cases, infection can cause inflammation that directly causes 
miscarriage, but there is no reason to suspect that women who experience inflammation-
induced miscarriage fail to benefit from the increase in TReg concentrations that occur with 
seminal fluid exposure,32–35 conception, and implantation,32,37 albeit insufficient 
immunosuppression to maintain the pregnancy to completion.
Recurrent miscarriage, defined as 3 or more consecutive miscarriages, is a rarer condition 
affecting an estimated 1% of pregnancy-attemptant women and can be caused by endocrine, 
autoimmune, or thrombotic abnormalities,77 with the latter, sometimes, possibly caused by 
cytokine degradation of vasculature.81 Because only 4% (N = 4) of the women in our cohort 
experienced a total of 3 or more miscarriages (Table 1), we suspect a low rate of recurrent 
miscarriage and thus a low degree to which incomplete pregnancy rates would be caused by 
the immunodysfunction associated with recurrent miscarriage. Similar to the argument 
above, there is no reason to suspect that women who experience inflammation-induced 
miscarriage fail to benefit from the increase in TReg concentrations that characterize the 
early stages of pregnancy, even if those changed are insufficient for successful gestational 
maintenance. The degree to which TReg proliferation occurs and is sustained in incomplete 
pregnancies is a question that requires further study. For now, there is no evidence to predict 
that experiencing a miscarriage would undermine our hypothesis of long-term 
immunoregulatory benefits of gestation.
Future research should expand upon our understanding of how reproductive history affects 
inflammatory mechanisms in the long term. More information is especially needed on the 
effects of pregnancy on T-cell activity in mothers with and without inflammatory diseases. It 
will be important for studies to consider the presence of pro-inflammatory alleles in 
understanding how immune system development, pregnancy, and other inflammation-related 
mechanisms affect AD risk. Further research is also needed to elucidate whether each 
pregnancy in a woman’s life history confers equivalent long-term changes to immune and 
endocrine systems.82
Conclusion
Using data from a cohort of elderly British women, we calculated cumulative time each 
woman spent pregnant and fit Cox models to test the statistical dependence of AD risk on 
pregnancy history. We found that more months pregnant in the lifetime was associated with 
reduced risk of AD. The more typically consulted but less comprehensive construct, parity 
(number of deliveries), exhibited no significant effect. Cumulative number of first—but not 
third—trimesters conferred a protective effect against AD risk. These observations are 
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consistent with a protective effect of pregnancy-induced proliferation of TRegs. Reproductive 
life history has an effect on maternal immune function, and there may be long-term impacts 
from immune cell proliferation that occurred during a woman’s reproductive years. 
Pregnancy is characterized by an immunosuppressive profile, and the increase in 
concentration of regulatory immune cells may have implications for inflammatory 
propensity in later life. We hope our findings prompt further study of this previously 
overlooked mechanism as a possible link between women’s reproductive life history and 
AD.
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Figure 1. 
Women with more cumulative months pregnant had lower AD risk. For each age, the plot 
reports the covariate-adjusted probability of being AD-free for women with total lifetime 
number of months pregnant below the cohort median (lower curve) and above the cohort 
median (upper curve). Pointwise 95% confidence bands are also shown. The purpose of this 
plot is to give a visual sense of the magnitude of the effect by dichotomizing the number of 
cumulative months pregnant variable. Cox regression of the reliance of AD risk on median-
split dichotomous characterization of cumulative months pregnant demonstrates that women 
above the cohort median exhibit 37.01% lower AD risk compared with women below the 
cohort median (β = −.99, exp(β) = .37, se(β) = .40, P =.01, 95% CI = 0.17–0.81). The Cox 
model reported in Table 2 represents a more meaningful analysis by utilizing the continuous 
cumulative months pregnant variable. AD indicates Alzheimer’s disease; CI, confidence 
interval.
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